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Abstract 
The second messenger cyclic adenosine monophosphate (cAMP) is ubiquitous and directs a 
plethora of functions in all cells. Although theoretically freely diffusible through the cell from 
the site of its synthesis it is not evenly distributed. It rather is shaped into gradients and these 
gradients are established by phospodiesterases (PDEs), the only enzymes that hydrolyse 
cAMP and thereby terminate cAMP signalling upstream of cAMP’s effector systems. Miles D. 
Houslay has devoted most of his scientific life highly successfully to a particular family of 
PDEs, the PDE4 family. The family is encoded by four genes and gives rise to around 20 
enzymes, all with different functions. M. Houslay has discovered many of these functions and 
realised early on that PDE4 family enzymes are attractive drug targets in a variety of human 
diseases, but not their catalytic activity as that is encoded in conserved domains in all family 
members. He postulated that targeting the intracellular location would provide the specificity 
that modern innovative drugs require to improve disease conditions with fewer side effects 
than conventional drugs.  
Due to the wealth of M. Houslay’s work, this article can only summarize some of his discov-
eries and, therefore, focuses on protein-protein interactions of PDE4. The aim is to discuss 
functions of selected protein-protein interactions and peptide spot technology, which M. 
Houslay introduced into the PDE4 field for identifying interacting domains. The therapeutic 
potential of PDE4 interactions will also be discussed.  
 
Keywords: phosphodiesterase, A-kinase anchoring protein; drug targets; cAMP; compart-
mentalisation; protein kinase A; protein-protein interaction;  
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1. Introduction to compartmentalized cAMP signalling 
Cells perceive changes of their environment through sensing chemical cues such as hor-
mones or neurotransmitters via receptors. Stimulation of receptors then causes a rise in the 
level of second messengers, which modulate intracellular signalling to enable cellular re-
sponses that are specific for each of those cues.  
Many of the cues stimulate G protein-coupled receptors (GPCRs), causing activation of the 
stimulatory G protein GS. The activated G protein, in turn, stimulates adenylyl cyclases to 
synthesise cyclic adenosine monophosphate (cAMP). This ubiquitous second messenger 
activates its effectors: protein kinase A (PKA), Exchange factors directly activated by cAMP 
(Epac1 and Epac2) and cyclic nucleotide-gated channels (CNGC), which will then initiate 
signalling cascades that orchestrate a cellular response that is specific to a particular cue. 
Considering that most of the cues selectively activate their cognate receptors, it is not sur-
prising that each elicits a specific cellular response. However, the question arises of how a 
ubiquitous second messenger such as cAMP can elicit specific responses if its level rises in 
response to numerous stimuli and upon activation of a whole variety of receptors, often at the 
same time in the same cell. A classical example is in cardiac myocytes. While prostaglandin 
E1 (PGE1) through E-prostanoid (EP) receptors and adrenergic agonists through β-
adrenoceptors both increase cAMP to similar levels, only the stimulation of β-adrenoceptors 
increases contractility. It is now clear that the level of cAMP does not increase uniformly but 
rather in microdomains where then cAMP effectors are activated. In the case of cardiac myo-
cytes, stimulation with PGE1 and β-agonists leads to activation of different pools of PKA [1-
4].  
Microdomains of cAMP are established by adenylyl cyclases synthesizing it and by phos-
phodiesterases (PDEs). PDEs are the sole means for cAMP degradation and prevent its uni-
form cellular distribution as they are strategically positioned and thereby establish gradients 
of cAMP that are sensed by its effectors. PDEs are tethered to subcellular compartments 
through direct association with membranes [5, 6], or through interactions with proteins that 
direct them to defined compartments. Protein binding partners include scaffolding proteins 
such as the A-kinase anchoring proteins (AKAPs), a heterogeneous family of around 50 pro-
teins characterised by their common ability to directly interact with PKA [7, 8]. In addition to a 
conserved domain for the interaction with PKA, AKAPs posses docking domains for direct 
binding of additional proteins such as PDEs and they possess anchoring domains tethering 
the AKAP-based protein complex to defined cellular compartments [9, 10]. It is this tethering 
of PDEs to defined cellular compartments that is a crucial component of the safeguard sys-
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tem conferring specificity to cAMP signalling. PDEs are critical for maintaining cAMP micro-
domains.  
2.  PDEs 
2.1 The PDE4 family of phosphodiesterases  
There are 21 genes encoding 11 families of PDEs, PDE1-11. The genes contain multiple 
promoters giving rise to >100 mRNAs and thus to >100 isozymes. PDEs hydrolyse cAMP 
and/or cGMP. The PDE4, PDE7, and PDE8 family enzymes specifically hydrolyse cAMP, the 
PDE5, PDE6, and PDE9 enzymes are cGMP-specific, while the PDE1, PDE2, PDE3, 
PDE10, and PDE11 family members hydrolyse both cAMP and cGMP. The individual en-
zymes differ in structure, regulation, location and pharmacological properties [11-14].  
The PDE4 family is the largest of the eleven PDE families. Four genes encode the PDE4A, 
B, C and D family isoforms; due to alterna-
tive start sites and alternative splicing 
around 25 isozymes are generated. The 
isoforms are long, short, super-short or 
dead-short, depending on which domains 
are present (Fig. 1A). All isoforms contain a 
highly conserved catalytic domain, N-
terminally from it upstream conserved re-
gions (UCR) 1 and 2 of variable length and a 
unique N-terminal region (NTR). They pos-
sess unique C termini [15]. The unique N-
terminal regions are involved in targeting the 
enzymes to defined cellular compartments. 
UCR1 largely mediates dimerization of the 
long isoforms. The absence of UCR1 ren-
ders the short forms of PDE4 monomeric. 
Additional regions within the catalytic domain 
were mapped which mediate dimerization of 
short forms (see below) [16]. PDE4 isoforms 
are constitutively active enzymes. The KM cAMP values for the PDE4 enzymes range from 1-
20 µM [17]. The KM cAMP hydrolysis for human PDE4D3 is 1.2 µM and the Vmax approxi-
mately 30 nmol/min/mg [17, 18]. PKA phosphorylation of the long isoforms enhances the 
hydrolytic activity. For example, PKA phosphorylation of S54 in UCR1 of PDE4D3 increases 
the Vmax for cAMP hydrolysis of rat PDE4D3 by about 50 % without affecting the KM. [19, 20]. 
  
Fig. 1. Schematic representation of long, 
short, super-short and dead-short isoforms 
encoded by A) the 21 PDE genes and B) 
by the PDE4D encoding gene. N and C 
term., N and C terminus, respectively; 
UCR, upstream conserved region. 
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In contrast, ERK2 phosphorylation of a conserved site in the C terminus of long isoforms of 
PDE4B, C and D inhibits their activity. ERK2 phosphorylation of S579 of human PDE4D3 
inhibits it by around 75 % [21, 22] 
 
2.2 Protein-protein interactions tether PDE4 isozymes to subcellular compartments 
Light was shed on the mechanisms underlying the compartmentalisation of PDE4 isozymes 
when interacting partners were identified. Classical scaffolding proteins tethering their inter-
acting partners to defined cellular locations are AKAPs. An early joint discovery by the 
groups of Houslay and Scott was that mAKAP tethers PDE4D3 together with PKA to the per-
inuclear compartment [23]. This protein assembly establishes a negative feedback loop for 
the local control of cAMP hydrolysis. An increase of cAMP leads to activation of mAKAP-
bound PKA, which in turn phosphorylates PDE4D3, enhancing its activity and thereby termi-
nating cAMP-mediated activation of PKA. The mAKAP complex controls several cardiac my-
ocyte functions. For example, in response to β-adrenoceptor stimulation mAKAP-bound PKA 
can phosphorylate Ryanodin type 2 receptors (RyR2) and enhance Ca2+-induced Ca2+ re-
lease through from the sarcoplasmic reticulum. This increases contractility of the myocyte 
[24]. 
Around the same time the groups of Conti and Tasken discovered an interaction of AKAP450 
with PDE4D3 on centrosomes [25]. Similar as the mAKAP interactions with PKA and 
PDE4D3 the AKAP450 complex introduces a negative feedback loop for cAMP signalling in 
close proximity of centrosomes.  
Antidiuretic hormone (arginine-vasopressin, AVP) induces the redistribution of the water 
channel aquaporin-2 (AQP2) from intracellular vesicles into the plasma membrane of renal 
collecting duct principal cells. The membrane insertion of AQP2 facilitates water reabsorption 
from primary urine and fine-tunes body water homeostasis. AVP induces a rise of cAMP fol-
lowed by PKA activation and phosphorylation of AQP2 by PKA, which is the trigger for the 
redistribution [10, 26, 27]. Together with M. Houslay we discovered an AKAP18δ-based sig-
nalling module on AQP2-bearing vesicles. [28]. AKAP18δ directly interacts with PDE4D3. It 
tethers PDE4D3 together with PKA to AQP2-bearing vesicles where PDE4D3 maintains low 
levels of cAMP under resting conditions and thereby prevents inappropriate activation of PKA 
and thus inappropriate water reabsorption. AVP stimulation of the principal cells increases 
cAMP and leads to PKA phosphorylation of PDE4D3 to enhance its activity. If cAMP reaches 
threshold levels PKA phosphorylates AQP2 and AQP2 redistributes into the plasma mem-
brane. The PKA-phosphorylated form of PDE4D3 co-translocates to the plasma membrane 
and hydrolyses cAMP to basal levels and resets the system, i.e. PKA becomes inactivated 
and AQP2 is endocytosed [28-30]. 
PDE4 species can directly interact with plasma membrane receptors such as PDE4A4/5 with 
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the p75 neurotrophin receptor (p75NTR) [31]. Tissue repair may be limited by scar formation. 
A critical component in the process of scarring is an initial fibrin deposition. During tissue 
repair fibrin is cleared by the serine protease plasmin. p75NTR is up-regulated upon tissue 
damage and regulates the proteolytic activity of plasmin by simultaneously down-regulating 
tissue plasminogen activator (tPA) and up-regulating plasminogen activator inhibitor-1 (PAI-
1) via a cAMP/PKA pathway. p75NTR directly interacts with PDE4A4/5, which locally de-
creases cAMP and reduces extracellular proteolytic activity. Thus the p75NTR-PDE4D5 in-
teraction contributes to pathology [31]. 
While mAKAP and AKAP450 are located constitutively at a particular cellular compartment 
and thus maintain their PDE4D interacting partner at that location PDE4D species may also 
alter their location depending on the state of the cell. Stimulation of β-adrenoceptors acti-
vates the Gs/adenylyl cyclase system and leads to a rise in cAMP. For signal termination the 
receptor is desensitized by binding of β-arrestin. In HEK293 cells, PDE4D directly binds β-
arrestin; under resting conditions the complex resides in the cytosol. This redistribution of β-
arrestin to the receptor is associated with a co-redistribution of PDE4D5 to the receptor and 
local cAMP hydrolysis. Thus PDE4D contributes to terminating β-adrenoceptor signalling 
[32]. The β-adrenoceptor-induced rise in cAMP leads to PKA activation and PKA-catalysed 
phosphorylation of the receptor, which, in turn, switches receptor coupling from Gs to the 
inhibitory G protein, Gi. Gi activates the extracellular signal-regulated kinases ERK1/2 and 
Akt. In cardiac myocytes activation of these pathways contributes to stress-induced hyper-
trophy. Gi inhibits adenylyl cyclase and thus cAMP synthesis. The β-arrestin-dependent re-
cruitment of PDE4D to the receptor and the local cAMP hydrolysis contributes to inhibition of 
PKA and reduction of receptor phosphorylation. Thus the β-arrestin-associated pool of 
PDE4D is associated with a switch from GS to activation of Gi [33].  
β-arrestin is not the only scaffolding protein that directs PDE4 isoforms into the cytosol. Re-
ceptor of activated C kinase 1 (RACK1) is a cytosolic scaffolding protein, although also asso-
ciated with ribosomes and plasma membrane receptors. It does not posses own catalytic 
activity but represents a platform for protein complex assembly, and supports docking, scaf-
folding, stabilizing, inhibiting and linking components of the complexes together. RACK1 
plays a role in diverse processes such as virus infection, neuronal development, cell migra-
tion, and angiogenesis [34, 35]. The 88 amino acids long unique N terminus of PDE4D5 con-
tains a RACK-binding site (RIAD1) [36, 37], and also the binding site for β-arrestin. The bind-
ing of PDE4D5 to RACK1 and β-arrestin is mutually exclusive [38]. In HEK293 cells, the in-
teraction of PDE4D5 with these two binding partners seems in equilibrium. Disturbing this 
equilibrium, e.g. by knockdown of RACK1 causes increased association of PDE4D5 with β-
arrestin, which upon stimulation of β-adrenoceptors leads to a decrease in PKA phosphoryla-
tion of the β-adrenoceptor since β-arrestin causes an enhanced accumulation of PDE4D5 at 
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the receptors [38]. 
The given examples of protein-protein interactions compartmentalising PDE4 isozymes are 
by no means exhaustive. For example, the N termini of PDE4A4/5 and PDE4D4 interact with 
the SH3 domains of Src family tyrosine kinases such as Lyn, Fyn, and Src [39, 40]; further 
interactions such as with myomegalin, Shank2 and Disc1 have been identified [11, 13-15]. In 
addition, direct membrane association can also compartmentalize a few PDE4 isozymes. 
One example is the tryptophan anchoring phosphatidic acid selective-binding domain 1 
(TAPAS-1 domain) of PDE4A1. The N terminus of PDE4A1 contains two helices separated 
by a hinge region. The second helix contains the TAPAS-1 domain, which mediates an inter-
action with phosphatidic acid and insertion into lipid bilayers. Selectivity for phosphatidic acid 
is achieved by a network of charges on the surface of the helical TAPAS-1 domain [5, 6]. The 
PDE4 orthologue of Aplysia, ApPDE4 exists in short and long forms, which are distinctly tar-
geted to different membrane compartments. The long form is targeted to intracellular mem-
branes through an N-terminally 16 amino acids long hydrophobic region, whereas the short 
form seems to exclusively interact with the plasma membrane through electrostatic interac-
tions of the N terminus with negatively charged membrane lipids such as PI4P and 
PI(4,5)P2. The membrane association of both the long and the short forms is enhanced by 
oligomersation through UCR1 and UCR2 [41]  
 
2.3 Peptide Spot arrays for mapping protein-protein interactions down to the level of 
individual amino acids 
Crucial to the understanding of protein-protein interactions of PDEs and thus to understand-
ing the molecular mechanisms underlying compartmentalization is the characterisation and 
mapping of the interacting domains. The mapping can be achieved by incubation of truncat-
ed recombinant versions of two interacting partners and co-precipitation. Truncating both 
proteins to a size that precludes co-precipitation will define the interacting regions. An alter-
native to this approach is to initially attempt co-precipitation of two proteins either from cell 
lysates or of recombinant proteins to show complex formation, and then to test whether the 
interaction is direct. Direct interactions can be elucidated by a combination peptide spot array 
technology and overlay with recombinant proteins. This approach simultaneously maps the 
interacting domains down to the single amino acid level. 
Ronald Frank originally invented the peptide spot technology [42, 43]. Libraries of peptides 
each up to 30 amino acids in length can be generated by automatic SPOT synthesis on cel-
lulose membranes or glass supports using Fmoc (9-fluorenylmethyloxycarbonyl) chemistry 
and automatic devices (e.g. Autospot-Robot ASS 222, Intavis Bioanalytical Instruments, 
50933 Koeln, Germany) [44]. An advantage of the technology is the possibility of parallel 
synthesis of hundreds or thousands of peptides with different sequences. Each amino acid in 
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any peptide can be substituted with any other amino acid. Single, double and multiple substi-
tutions may be introduced. Particular informative and widely used are alanine substitutions. 
An interaction of the spot-synthesised peptides with a putative binding partner is detected by 
a modified Western blotting procedure (Far Western blot). The peptides are often overlaid 
with fusions of the recombinant putative binding partner and glutathione S-transferase (GST). 
Then a GST overlay would be carried out as a negative control. A specific antibody directed 
against the putative binding partner and a suitable secondary antibody are applied. The sec-
ondary antibody is either linked to an enzyme such as horseradish peroxidase or alkaline 
phosphatase, catalysing a reaction that permits detection of a colour or the secondary anti-
body can be linked to a fluorescent moiety. Either detection of a developing colour or of fluo-
rescence allows for visualisation of the interaction. This method can detect continuous and 
discontinuous binding sites. Identified interactions are validated by co-precipitation studies. 
The binding sites are usually located on the surface of proteins and if 3D structures are 
available can be mapped on the protein structure.  
Moreover, analysis of posttranslational modifications such as ubiquitination, sumoylation and 
phosphorylation of peptides may be carried out by incubating spot-synthesised peptides with 
the enzymes catalysing such reactions. For example, 25mer peptides encompassing amino 
acid residues 22-28 of PDE4D5 were sumoylated at a sumoylation consensus motif, VKTE-
QED motif [45]; PKA phosphorylated sites (S428 and S438) in 30 mer peptides derived from 
PDE3A [46].  
A drawback of the method is the limit of peptide length, 30 amino acids are currently consid-
ered the maximum. The synthesis of longer and difficult peptides can lead to impurities, syn-
thesis termination and thus low yields. Inter- and intramolecular aggregation and sterical hin-
drance is a further potential problem. To minimize this cysteines are usually replaced by ser-
ines for example [44]. 
Identification of interacting domains and defining the contribution of individual amino acids to 
the interactions by a combination of the peptide spot technology with overlay techniques has 
been of utmost importance for understanding PDE4 isozyme interactions. For example, the 
interaction of p75NTR and PDE4A5 [31], of AKAP18δ with PDE4D3 [28] and that of MEK1 
and β-arrestin-1 [47] have been mapped using this technology; and the technology also al-
lowed for defining overlapping binding sites for β-arrestin and RACK1 in PDE4D5 [38]. 
 
3. PDE4 isozymes’ protein-protein interactions as drug targets in human diseases 
PDE4 enzymes are expressed almost ubiquitously. In particular they are found in airway and 
vascular smooth muscle cells, leukocytes and in the brain and are involved in major diseases 
such as inflammatory and neurological disorders. The ubiquitous expression and the high 
conservation of the catalytic domains of PDE4 family members represent the major obstacles 
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for clinical applications of PDE4 inhibitors. The use of rolipram, a selective PDE4 inhibitor 
that targets the catalytic domain, has documented, catalytic domains of PDE4 enzymes are 
difficult targets for the treatment of human disease. Rolipram causes nausea and emesis, 
side effects not tolerated by patients. However, over the last few years inhibitors that over-
come the dose-limiting side effects caused by rolipram have emerged and a few have 
reached the market. The first approved PDE4 inhibitor was roflumilast in 2010 as an add-on 
therapy for chronic obstructive pulmonary disease (COPD). With apremilast a second PDE4 
inhibitor reached the market in 2014. It is approved for the treatment of psoriatic arthritis. 
Both roflumilast and apremilast are non-selective inhibitors of PDE4A-D. Although they are 
effective drugs they still can cause emetic side effects. Current developments of a new gen-
eration of anti-PDE4 drugs follow different strategies. One concept is to develop conforma-
tional state-directed ligands. Roflumilast is an example for an inhibitor that binds preferential-
ly to a state of PDE4 enzymes that is associated with low affinity binding of rolipram. In addi-
tion, antagonists are being developed that isoform-selectively target catalytic sites of PDE4A, 
B, C or D, and allosteric inhibitors. In any case, the aim of all of these developments is to 
separate the unwanted side effects, in particular nausea and emesis, from the therapeutically 
beneficial ones. 
Maybe the most promising strategy to reach this goal is displacement of PDE4 enzymes from 
their cognate cellular location to which they are tethered through a protein-protein interaction. 
Protein-protein interactions are highly specific and diverse and, therefore, provide superb 
opportunities for a highly selective pharmacological interference. A drawback is that proteins 
often interact through extended shallow surfaces of around 1.000-2.000 Å2, which cannot be 
blocked by binding of a small molecule. Small molecule drugs preferably possess a molecu-
lar weight of around 500. However, specific amino acid residues within the interacting do-
mains often provide the critical energy for the interaction. These “hot spots” can be targeted 
by small molecules [48, 49].  
M. Houslay was one of the first to realise that selectively enhancing local cAMP by displace-
ment of specific PDE4 isoforms may protect against the unwanted side effects of global 
PDE4 inhibition. One approach is using dominant negative versions of a PDE4. They are 
catalytically inactive and upon overexpression displace the endogenous PDE4 from its bind-
ing partner. The consequence would be a local rise of cAMP and an increased local PKA 
activity. For example, the catalytically inactive PDE4D5-D556A prevents the isoproterenol-
induced binding of the endogenous PDE4D5 to the β2-adrenoceptor complex. This is associ-
ated with an activation of ERK1/2 and thus caused by a local rise in cAMP, PKA activation 
and G protein switching from Gs to Gi (see 2.2) [33]. The dominant negative approach has 
for example also elucidated that PDE4D3 controls a cAMP microdomain at the β1-
adrenoceptor in cardiac myocytes [50] and that PDE4D3 and PDE4C2 control AKAP-
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anchored PKA activity in the perinuclear region [51]. The dominant negative approach can 
reveal relevant physiological mechanisms, and contribute to validate a target.  
The peptide array technology has provided the means for fine mapping of protein-protein 
interaction sites (see 2.3). Synthetic peptides can be derived from the binding regions of the 
interacting partners and rendered membrane-permeant by coupling to lipids such as stearate 
or a myristoyl group. Such peptides are valuable tools for targeting an intracellular protein-
protein interaction. Peptide spots representing the entire sequence of Lis1 were incubated 
with full length PDE4D3. This revealed two binding sites for the PDE, one of which between 
amino acid residues 226-250. A peptide encompassing this region was synthesised and ren-
dered membrane-permeant by coupling to stearic acid. The peptide prevented the interaction 
of LIS1–GFP and PDE4D3–VSV in HEK293 cells expressing [52]. Another example is a pep-
tide encompassed amino acids 6–29 of β-arrestin1, which inhibits the interaction of β-
arrestin1 with MEK1 in HEK293 cells [47].  
A recent example convincingly showing the merit of this concept relates to heat shock pro-
tein, HSP20. HSP20 protects the heart against sepsis- and endotoxin-induced cardiac dys-
function in mice [53] and overexpression of HSP20 reduced apoptosis upon ische-
mia/reperfusion (I/R) injury [54]. The cardioprotective effect of HSP20 is due to a phosphory-
lation of serine 16 by PKA. Overexpression of a phosphomimic (HSP20-S16D), i.e. constitu-
tively phosphorylated HSP20, in adult cardiac myocytes inhibited apoptosis [54, 55]. HSP20 
interacts directly with PDE4D5. The interaction site on PDE4D5 was mapped to amino acid 
residues V466–L490 in the catalytic domain by spot synthesizing the entire sequence of 
PDE4D5 and overlaying the peptides with recombinant HSP20. In a second step a peptide 
representing amino acid residues 468-492 of PDE4D5 was synthesized as a stearate-
coupled and thus membrane-permeant version. This peptide inhibited the interaction of 
HSP20 and PDE4D5 in HEK293 cells and increased the serine 16 phosphorylation. Moreo-
ver, in neonatal cardiac myocytes the peptide inhibited the isoproterenol-induced hypertro-
phy, it inhibited the isoproterenol-induced rise of the hypertrophy marker natriuretic peptide 
(ANP) by 50 % [56]. Moreover, in vivo in mice the peptides protected against cardiac remod-
elling after aortic banding, an animal model for heart failure [57, 58]. Thus the use of peptides 
suggests the interaction as a putative drug target for the treatment of heart failure, as cardiac 
hypertrophy represents an intermediate stage en route to heart failure. Alanine scans of the 
PDE4D5 region interacting with HSP20 using peptide spots revealed critical amino acids 
whose substitution with alanine abolished the interaction (H470, H471 K477, E481, E482 and 
D485) [56]. These amino acids may be considered hot spots and thus could be the starting 
point for the development of small molecules blocking the interaction. In addition to COPD 
and psoriasis for whose treatment PDE4 inhibitors are already approved (see above) there 
are several further major diseases associated with deregulation of PDE4 enzymes. Amongst 
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others cognitive enhancers [59] and asthma drugs [60] are currently being develop. They all 
target enzyme activities. However, there are disease-relevant PDE4 interactions in a number 
of instances. Examples are the interaction of PDE4A with p75NTR in fibrosis [31] or the in-
teraction of DISC1 with PDE4B in schizophrenia [61]. 
 
Concluding remarks 
The data discussed here show that specific functions have been ascribed to defined protein-
protein interactions of PDE4 family enzymes which suggest that they are potential drug tar-
gets in a variety of major diseases, including cardiac and inflammatory diseases as well as 
neurological disorders. Developing small molecule inhibitors of these interactions would pro-
vide unique opportunities for pharmacological intervention and may overcome the dose-
limiting side effects, in particular nausea and emesis, of the small molecule inhibitors that 
target the catalytic activity of PDE4 enzymes. With hot spots mapped, for example, in the 
HSP20 interacting domain of PDE4D5 [56] the grounds are laid for such developments. For a 
detailed understanding of PDE4-dependent protein-protein interactions structural analyses 
are needed. The structural analysis of PDE4 enzymes has so far mostly provided information 
about the catalytic units. 3D structures of PDE4 enzymes with their interacting partners 
would facilitate rational design of inhibitors. M. Houslay has had and still has (e.g.[62]) a 
great share in the elucidation of functions of PDE4 family enzymes and their protein-protein 
interaction.  
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